FINWIRES · TerminalLIVE
FINWIRES

AFT Pharmaceuticals Gets US FDA Nod for Phase 3 Trial of Injectable Iron Therapy

By

AFT Pharmaceuticals (NZE:AFT, ASX:AFP) said the US Food and Drug Administration allowed the company to proceed with a phase 3 clinical trial of its injectable iron deficiency therapy, according to a Wednesday filing with the Australian and New Zealand bourses.

AFT and development partner Hyloris Pharmaceuticals plan to launch a global confirmatory study involving 1,366 patients across multiple geographies including New Zealand, China, India, Japan, Armenia, Europe, and the US.

The therapy targets an addressable market estimated at $7.41 billion, per the filing.

The company's New Zealand shares gained 2% in recent Wednesday trade.

Related Articles

Asia

Tetratherix Joint Venture Gets Ethics Approval for Clinical Trial of Hydrogel Spacer in Cancer Treatments

Tetratherix (ASX:TTX) said its Tutelix joint venture received ethics committee approval to launch a clinical trial for hydrogel spacer in Australia, according to a Tuesday filing with the Australian bourse.The Tutelix hydrogel spacer is used during cancer treatments to protect healthy parts of the body from damage.Positive six-month follow-up data confirms an opportunity for the product beyond the prostate cancer program, providing the company with a technical basis to pursue a gynaecological cancer indication, Tetratherix Chief Technology Officer Ali Fathi said.The clinical study has completed enrolment of all 15 patients across multiple Australian sites, per the filing.

ASX:TTX
Asia

Bharat Electronics Bags New Orders Worth INR10.8 Billion

Bharat Electronics (NSE:BEL, BOM:500049) has secured additional orders worth 10.8 billion Indian rupees within one month, according to a filing to the Indian stock exchanges on Monday.Major orders received since May 25 include communication equipment, radars, CBRN protection systems, seekers, avionics, upgrades, spares, and services, among others.

BOM:500049NSE:BEL
Asia

Chasen Secures Solar, EV Contracts in India

Chasen 9 (SGX:5NV) secured around 470 million Indian rupees worth of solar energy and electric vehicle battery contracts in India, according to a Monday filing with the Singapore Exchange.The deals include an electronics manufacturing services contract for specialist relocation services and an integrated solar manufacturing facility contract commissioned at the Reliance Industries' Dhirubhai Ambani Green Energy Giga Complex in Gujarat.

SGX:5NV